Search the Newsreel

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Immix Biopharma, Inc. (NASDAQ: IMMX) following revelations about the company's former Chief Medical Officer, Richard Graydon, who was allegedly a fugitive named Ronald L. Fischer. Fischer had disappeared during a rape trial in …

Summit Hotel Properties (NYSE:INN) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Marcus & Millichap Brokers $5.3M Sale of Multifamily Property in Miami Beach Florida

Marcus & Millichap has announced the sale of an 24-unit multifamily property in Miami Beach, Florida, for $5.3 million. The property was purchased by a New York-based private investment group, indicating continued strong demand from nonlocal investors for South Florida real estate. The asset, …

Marcus & Millichap (MMI) Q2 Results Put Its Valuation Back In Focus

Marcus & Millichap (MMI) reported its Q2 2026 results, showing a return to profitability and continued capital returns through buybacks and dividends, which garnered fresh attention. While the company's stock has seen recent positive momentum, Simply Wall St's analysis suggests it is 11.6% overvalued …

Marcus & Millichap Q2 2026 slides: profitability returns amid CRE recovery

Marcus & Millichap reported a significant return to profitability in Q2 2026, beating analyst expectations with revenue of $202.9 million, up 17.8% year-over-year. The company saw net income turn positive to $3.9 million from an $11.0 million loss, and Adjusted EBITDA surged 732.6% to …

Summit Hotel Properties, Inc. Q2 2026: Revenue $199M, EPS $0.04— 10-Q Summary

Summit Hotel Properties, Inc. reported its Q2 2026 financial results, achieving $199M in revenue and diluted EPS of $0.04, showcasing year-over-year growth in revenue and improved profitability compared to Q2 2025. Key factors included a 3.2% increase in revenue, a positive net income of …

Earnings call transcript: Summit Hotel beats Q2 2026 estimates but shares fall

Summit Hotel Properties (INN) exceeded Q2 2026 earnings expectations, reporting adjusted EPS of $0.04 against a forecast loss of $0.05, and revenue of $199.02 million, slightly above estimates. Despite raising its full-year guidance due to stronger hotel performance, the company's stock fell by 2.79% …

Press Release: SUMMIT HOTEL PROPERTIES REPORTS SECOND QUARTER 2026 RESULTS

This press release from Summit Hotel Properties reports their financial results for the second quarter of 2026. It provides key performance indicators and a summary of the company's financial health during that period.

Summit Hotel Properties Is Overheating (Downgrade) (NYSE:INN)

Cummins Stock And 2 US Industrial Names Backed By Data Center And Infrastructure Demand

News | Summit Hotels CEO: Second-quarter success about 'more than the World Cup'

Summit Hotel Properties CEO Jonathan Stanner reported strong second-quarter results, emphasizing that success extended beyond the FIFA World Cup due to a broad lift in business transient and group travel. The company saw meaningful revenue per available room and earnings growth in various urban …

Marcus & Millichap, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MMI) 2026-08-06

Marcus & Millichap, Inc. (MMI) released its Q2 2026 earnings call presentation. The slide deck provides detailed results discussed during the call. The article was prepared by SA Transcripts, which focuses on publishing quarterly earnings call transcripts.

Marcus & Millichap Brokers Sale of Six-Property Self-Storage Portfolio in Oregon

Marcus & Millichap has successfully brokered the sale of a six-property self-storage portfolio in Oregon, comprising 3,545 units across 537,962 square feet. The portfolio, known as Secure Storage, includes facilities in Ashland, Bend, Prineville, Redmond, Hood River, and Hillsboro, with two properties offering land …

Earnings Flash (MMI) Marcus & Millichap, Inc. Reports Q2 Revenue $202.9M, vs. FactSet Est of $194.3M

Marcus & Millichap, Inc. (MMI) reported stronger-than-expected Q2 revenue of $202.9 million, surpassing FactSet's estimate of $194.3 million. This positive earnings flash indicates a robust financial performance for the real estate services company during the second quarter of 2026. The company also announced a …

Marcus & Millichap (NYSE:MMI) Surprises With Strong Q2 CY2026

Marcus & Millichap (NYSE:MMI) reported stronger-than-expected revenue and GAAP profit for Q2 CY2026, with sales up 17.8% year-on-year to $202.9 million and EPS of $0.10, significantly beating analyst estimates. Despite a historical decline in long-term revenue and EPS growth, the company showed improved operating …

Marcus & Millichap Posts $3.9M Q2 Profit After Year-Earlier Loss

Marcus & Millichap (MMI) reported a Q2 2026 net income of $3.9 million, or $0.10 per diluted share, a significant turnaround from a net loss of $11.0 million in Q2 2025. This improvement was driven by a 17.8% increase in total revenue to $202.9 …

Cummins India stock outlook: Why this earnings-led fall may not derail the rally

Marcus & Millichap (NYSE: MMI) posts Q2 2026 revenue of $202.9M

Marcus & Millichap reported a return to profitability in Q2 2026, with total revenue increasing by 17.8% to $202.9 million and net income reaching $3.9 million, or $0.10 per diluted share, compared to a net loss in the prior year. The company also declared …

Shimmick Corporation $SHIM Stock Position Lowered by Sanders Morris Harris LLC

Cummins Inc. $CMI Shares Sold by Hamlin Capital Management LLC

Hamlin Capital Management LLC reduced its stake in Cummins Inc. (NYSE:CMI) by 8.8% in the second quarter, selling 37,217 shares, though Cummins remains its largest holding at 6.2% of its portfolio. Cummins reported strong Q2 revenue of $9.46 billion, exceeding estimates, and raised its …

Summit expands ivonescimab's challenge to Keytruda into bladder cancer

Summit Therapeutics is expanding its ivonescimab development beyond lung cancer by initiating the HARMONi-GU1 Phase II/III trial for bladder cancer. This trial will test ivonescimab plus Astellas/Pfizer's Padcev against Merck's Keytruda plus enfortumab vedotin for first-line treatment of advanced urothelial carcinoma. The company aims …

Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates

Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder …

Cummins India Shares Slip 4% After Q1 Profit Declines; Nomura Maintains 'Neutral'

Cummins India shares fall 3.98% among top losers on Nifty Next 50

Cummins India Q1 Results: Brokerages Divided, But Expert Remains Bullish On The Stock's Outlook

Summit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer

Summit Therapeutics has launched the HARMONi-GU1 trial, a global Phase II/III study evaluating ivonescimab in combination with an antibody-drug conjugate for bladder cancer. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF pathways. This trial represents an expansion of Summit's HARMONi program, …

$Farmmi (FAMI.US)$ $FAMI just got news after hours. Only 41 million Float👀

A Moomoo user highlights that Farmmi (FAMI.US) received after-hours news, noting its low float of 41 million shares. The stock, which had fallen from over $1.30, has been trading between $0.15-$0.22, suggesting significant gap-up potential from its current price of $0.1645. Key developments mentioned …

Cummins India shares fall over 4% after Q1 earnings, MD resignation

Cummins (CMI) Stock Looks Below Fair Value Though Earnings Look Rich

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cummins stock has delivered a very strong 5 year run, yet the current checks present a mixed message, with the intrinsic value estimate from a …

Cummins (CMI) Is Up 7.3% After Record Q2 Results, Higher 2026 Outlook And Dividend Hike

Cummins Inc. reported past second-quarter 2026 results with sales of US$9,457 million and net income of US$932 million, as earnings per share from continuing operations increased modestly year on year. The company paired these record quarterly sales with a higher full-year 2026 revenue growth …

Cummins’ Q2 Earnings Missed on Margins. Free Cash Flow Beat by 150% Anyway.

Summit Hotel Properties (INN) Q2 FFO and Revenues Beat Estimates

Cummins Inc. Earnings Call Signals Profitable Growth

Cummins Inc. reported a robust Q2 with record revenue of $9.5 billion, a 9% year-over-year increase, and record EBITDA of $1.7 billion. The company raised its full-year revenue growth guidance to 10%-13% and EBITDA margin outlook to 18%-18.5%, driven by strong demand in power …

Cummins (CMI) Could Be 13% Undervalued After Record Q2 And Higher Guidance

Summit Hotel Properties (NYSE:INN) Issues FY 2026 Earnings Guidance

Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study

Summit Therapeutics (NASDAQ: SMMT) has initiated the global Phase II/III HARMONi-GU1 study for ivonescimab in urothelial carcinoma (bladder cancer). This randomized trial will evaluate ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin as a first-line treatment for locally advanced or metastatic urothelial carcinoma, …